Clinical applications of bacterial glycoproteins

From National Research Council Canada

DOIResolve DOI: https://doi.org/10.1586/14789450.2016.1166054
AuthorSearch for: 1 ; Search for: ; Search for: 1 
Name affiliation
  1. National Research Council Canada. Human Health Therapeutics
FormatText
TypeArticle
Journal titleExpert Review of Proteomics
ISSN1478-9450
1744-8387
Volume13
Issue4
Pages345–353
SubjectInfectious disease; Bacterial pathogen; Host-pathogen interactions; Antibiotic resistance; Virulence factor; Pathogenesis; Glycoprotein; Diagnostics; Vaccines; Bacterial therapeutics
Abstract
There is an ongoing race between bacterial evolution and medical advances. Pathogens have the advantages of short generation times and horizontal gene transfer that enable rapid adaptation to new host environments and therapeutics that currently outpaces clinical research. Antibiotic resistance, the growing impact of nosocomial infections, cancer-causing bacteria, the risk of zoonosis, and the possibility of biowarfare all emphasize the increasingly urgent need for medical research focussed on bacterial pathogens. Bacterial glycoproteins are promising targets for alternative therapeutic intervention since they are often surface exposed, involved in host-pathogen interactions, required for virulence, and contain distinctive glycan structures. The potential exists to exploit these unique structures to improve clinical prevention, diagnosis, and treatment strategies. Translation of the potential in this field to actual clinical impact is an exciting prospect for fighting infectious diseases.
Publication date
PublisherTaylor & Francis Group
Terms of use
LanguageEnglish
Peer reviewedYes
NPARC number23000117
Export citationExport as RIS
Report a correctionReport a correction
Record identifiera547aa96-b63b-43a5-95fa-77aee428efa2
Record created2016-06-03
Record modified2016-06-03
Date modified:
Report a problem on this page